© 2021 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
Breast Cancer
Artificial intelligence can predict risk of recurrence for women with common breast cancer
October 15, 2021
They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.
Why cancer outcomes could depend on AI care coordination
October 15, 2021
As we move beyond COVID-19, the healthcare industry is just beginning to uncover the impact of delayed cancer screenings and care on oncology outcomes.
FDA approves companion diagnostic for adjuvant abemaciclib plus endocrine therapy in high-risk early breast cancer
October 14, 2021
The FDA has approved the Ki-67 IHC MIB-1 pharmDx test to assist in determining which patients with early breast cancer who are at high risk of disease recurrence might benefit from adjuvant treatment with abemaciclib plus endocrine therapy.
Top 5 metastatic breast cancer stories
October 13, 2021
In honor of October 13 as National Metastatic Breast Cancer Awareness Day, Contemporary OB/GYN® has collected its top metastatic breast cancer articles over the past year.
FDA approves adjuvant abemaciclib plus endocrine therapy for select HR+ early breast cancer
October 13, 2021
The FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20% or higher, as determined by an FDA-approved test.
Data aid in treatment for vulvovaginal health, sexual function after cancer
October 11, 2021
Analyzing the relationship between data from patient self-reports and clinician ratings of vulvovaginal tissue health following cancer can help provide better sexual function treatment for patients, according to a recent study.
Sacituzumab govitecan-hziy improves quality of life in patients with metastatic triple-negative breast cancer
October 06, 2021
Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.
FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer
October 05, 2021
The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.
Gut health may impact tumor response to radiation
September 16, 2021
The overgrowth of fungi could cause the immune system to stop fighting cancer, according to a study.
Web-based tool for family cancer history information collection
September 16, 2021
In an interview with Targeted Oncology, Melissa K. Frey, MD, discussed findings from implementing web-based health information collection of family history in patients with gynecologic cancers.